Cytoimmune Therapeutics is at the forefront of developing innovative cell therapy solutions, particularly focusing on engineered natural killer (NK) cell immunotherapy. Their primary technology, the TRACK-NK™ platform, involves creating allogeneic, tumor-reactive NK cells that are designed to directly attack cancer cells while also stimulating the immune system through the secretion of interleukin-15 (IL-15). This dual mechanism is achieved by engineering NK cells to express chimeric antigen receptors (CAR) and a bispecific killer engager (BiKE), which enhances their ability to target tumors effectively. The company emphasizes the advantages of NK cells over traditional T cell therapies, including a lower risk of graft-versus-host disease and cytokine release syndrome, making their approach potentially safer and more effective for patients.

In addition to the TRACK-NK™ platform, Cytoimmune is also developing the CoalesceNT NK platform, which further enhances NK cell functionality through triple editing: the expression of a CAR, secretion of soluble IL-15, and secretion of a BiKE. This comprehensive engineering allows for improved tumor targeting and immune system activation. The company operates a fully integrated manufacturing facility in Puerto Rico, ensuring a robust supply chain for their cell therapies. With a focus on allogeneic, off-the-shelf solutions, Cytoimmune Therapeutics aims to provide accessible and effective cancer treatments that leverage the inherent anticancer properties of NK cells while minimizing associated risks.

United States

CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients.

Our CoalesceNT™ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.

Cancer

Digestive System Diseases

Endocrine System Diseases

Hematologic Diseases

Urogenital Diseases

Cytoimmune Therapeutics

Non-small cell lung carcinoma

CYTO NK-102

Cell Therapies

CYTO NK-102 (combination)

Bladder cancer

Cholangiocarcinoma

Pancreatic cancer

Prostate cancer

CYTO NK-203

Acute myeloid leukemia

CYTO NK-201

Multiple myeloma

CYTO NK-301

California - South

California

Biologics

CAR-T Immunotherapy

Therapeutic

Cytoimmune Therapeutics

Company Details